TLR2 and cancer: As TLR2 is conserved in mouse cDCs and their human counterparts, especially between murine CD8+ cDCs and the human equivalent CD141+ cDCs (22), agonists targeting TLR2 could be promising adjuvants in designing vaccines through activating DCs for cancer immunotherapy.